A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.
Latest Information Update: 12 Aug 2023
At a glance
- Drugs GSK 1018921 (Primary) ; Midazolam
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
Most Recent Events
- 11 Jul 2009 New trial record